Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | THPO | P40225 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | SHBG | P04278 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxymesterone SCHEMBL4317989 | 1.00 | CYP3A4 (0.69) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| Oxymesterone SCHEMBL141603 | 1.00 | CYP3A4 (0.69) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL9542851 | 0.90 | SHBG (0.57) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL9542854 | 0.90 | SHBG (0.57) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL9542574 | 0.88 | CYP3A4 (0.67) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL9542566 | 0.88 | CYP3A4 (0.67) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL23801605 | 0.87 | SHBG (0.57) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL9544690 | 0.87 | SHBG (0.57) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL7951228 | 0.87 | SHBG (0.57) | CYP3A4TSHRTHPOHIF1ATDP1 | |
| SCHEMBL9542783 | 0.87 | CYP19A1 (0.68) | CYP3A4TSHRTHPOHIF1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152348-A1 | SYSTEMS AND METHODS FOR COLLECTING, TRANSPORTING AND REPURPOSING OR DESTROYING UNUSED PHARMACEUTICALS | SHARPS COMPLIANCE, INC. OF TEXAS | 2015-06-04 | — | — | US | disclosed |
| US-20090123571-A1 | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| EP-1865955-A4 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20080207601-A1 | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence | HYTHIAM , INC. (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1868593-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | Hythiam, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1865955-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | Merck & Co., Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006110642-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006104762-A2 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123571-A1 | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | ADRA1D, ADRB1, AGER | CYP3A4 1077/4885TSHR 629/4885THPO 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.